1. Guidance for Industry: E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. 〈http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm129357.pdf〉. 17-09-2013.
2. Timing of new black box warnings and withdrawals for prescription medications;Lasser;J. Am. Med. Assoc.,2002
3. Can pharmacogenetics help rescue drugs withdrawn from the market?;Shah;Pharmacogenomics,2006
4. Dealing with global safety issues: was the response to QT-liability of non-cardiac drugs well coordinated?;Stockbridge;Drug Saf.,2013
5. Guidance for Industry: S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals. 〈http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm074963.pdf〉. 17-09-2013.